Elan to Settle Zonegran Investigation For $204 Million
From Associated Press (July 15, 2010)
NEW YORK -- Irish drugmaker Elan Corp. PLC said Thursday it
agreed to pay $203.5 million to settle investigations into sales
and marketing practices related to the epilepsy drug Zonegran.
Elan's U.S. division... (Source: Drugs.com - Pharma News)
MTRAC Effective Shared Care Agreement (ESCA) on the use of zonisamide (Zonegran) for the adjunctive treatment of partial epileptic seizures
The Midlands Therapeutic Review and Advisory Committee (MTRAC) has issued an Effective Shared Care Agreement (ESCA) on the use of zonisamide (Zonegran#174;) for the treatment of partial epileptic seizures. The document sets out the responsibilities and roles of the specialist, the GP and the patient. Supporting information is also provided. (Source: NeLM Headline News)
